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Tumour modelling using viral vectors
Ian J. Frew
Human tumours typically harbour multiple 
mutations in tumour suppressor genes and oncogenes. 
Histologically identical tumours in different patients often 
exhibit different combinations of genetic alterations and it 
is now also evident that considerable genetic heterogeneity 
can exist between cells within individual tumours. A 
major ongoing research challenge remains to determine 
the functional significance of this enormous genetic 
diversity and heterogeneity in terms of impact on tumour 
phenotypes and responses to therapies. Autochthonous 
mouse models of human tumours have provided many 
insights into the combinations of genetic alterations that 
are causal to tumour initiation and progression in different 
tissues. However, conventional germline-based genetic 
approaches, such as the generation of compound mutant 
mice based on transgenics and knockouts, are limited by 
the time and cost associated with extensive intercrossing 
of mouse lines. Faster and more powerful genetic tools are 
required to accelerate the functional annotation of cancer 
mutational cataloguing studies. Excitingly, several new 
viral vector-mediated genetic approaches offer the ability 
to directly modify the genome of somatic cells in mouse 
tissues and these have recently been applied to the rapid 
generation of complex mouse tumour models that harbour 
multiple genetic changes. 
The use of lentiviral gene delivery vectors for 
cancer modelling studies offers the advantage that the 
proviral DNA integrates into the genome of infected cells, 
providing heritability of the introduced genetic alterations. 
Injections of lentiviruses that co-express shRNAs against 
Trp53 and Nf1 or that co-express oncogenic Hras 
and shRNA against Trp53 were employed to generate 
autochthonous mouse models of glioma [1]. This study 
provided proof-of-principle that the lentiviral approach is 
a feasible tool for cancer modelling. Building upon this 
idea, we recently generated the MuLE lentiviral system 
(http://www.addgene.org/kits/mule-system/) that provides 
a highly flexible genetic toolbox allowing combinatorial 
gene knockdown, knockout, mutation or overexpression, 
together with tagging of infected cells with useful 
markers such as luciferase or fluorescent proteins [2]. 
We demonstrated the utility of this system for generating 
genetically complex autochthonous tumour models by 
showing that intramuscular injection of ecotropic MuLE 
lentiviruses expressing luciferase, oncogenic Hras and 
shRNAs against Cdkn2a or Trp53 or against both Trp53 
and Pten, induced the formation of pleomorphic sarcomas 
that could be quantitatively monitored using luciferase-
based imaging [2]. The histology of these tumours was 
indistinguishable from the pleomorphic sarcomas that 
arose through transgenic or adenoviral Cre-mediated 
genetic deletion of Trp53 and activation of oncogenic 
Kras in germline-modified mice [3,4], validating that the 
MuLE-mediated somatic genetics approach can rapidly 
and faithfully recapitulate tumour models obtained using 
conventional genetic strategies. 
Several genetically complex lung cancer models in 
mice have recently been generated using different types 
of viral vectors. Adenovirus and Adeno-associated virus 
(AAV) DNA remains episomal in infected mouse cells 
and is lost by dilution upon repeated cell division, which 
has historically limited the use of these vectors in tumour 
modelling. However, in the context of the CRISPR/Cas9 
system, the episomal nature of viral infection is in fact 
advantageous as the introduced viral DNA represents a 
template that can be used for homology directed repair 
following Cas9-induced DNA double strand breakage. 
Taking advantage of transgenic mice expressing Cre-
activatable Cas9, the intratracheal delivery of AAV9 
viruses expressing Cre, luciferase, sgRNAs against Trp53, 
Lkb1 and Kras, together with a template for homology 
directed repair to insert an oncogenic Kras mutant into 
the endogenous locus, allowed the generation of lung 
tumours driven by three different genetic mutations [5]. 
In another model, intratracheal delivery of lentiviruses 
expressing Cre, Cas9 and sgRNAs against different 
tumour suppressor genes into mice with conditional 
Trp53 and oncogenic Kras alleles provided a series of 
lung cancer models with complex genetic backgrounds 
[6]. Finally, infection of lung epithelia using an adenoviral 
vector expressing two sgRNAs and Cas9 allowed the 
generation of a lung cancer model driven by the Eml4-Alk 
chromosomal rearrangement [7].
These studies collectively highlight the new genetic 
power that is offered by the use of viral vector-mediated 
somatic genetics in wild type or germline modified mice. 
By employing different types of lentiviral, retroviral, 
adenoviral and AAV vectors, together with the use of 
cell-type specific promoters or infection of germline-
modified mice that allow cell type-specific Cre, tTA 
or rtTA expression, it should be possible to specifically 
direct genetic modulations to diverse somatic cell types. 
The ability to clone libraries (eg. shRNA or sgRNA) 
into these viral expression vectors will pave the way 
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for in vivo screens based on combinatorial genetics and 
will potentially allow experiments that better mimic 
intratumoural genetic heterogeneity. These new genetic 
tools will assist researchers in tackling the challenges of 
understanding the functional implications of the genetic 
complexities of human malignancies.
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